فهرست مطالب gracia pricilia

The most common cancer in women is breast cancer (BC) with an incidence of 24.2%. BC in younger patients will in general be more forceful, prompting more awful results and a requirement for more forceful treatment which may bring about a higher probability of long-haul treatment-related harmfulness and novel psychosocial issues. Furthermore, family inclination to BC as BRCA1 and BRCA2 mutations is more prevalent in this age group. There were a total of five ladies who had tumor pathology testing with negative results. All intrusive BC examples were regularly assessed for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2)/neu status utilizing immunohistochemistry. Cases with HER2/neu staining of 1+, 2+ or 3+ on immunohistochemistry examination were additionally assessed by fluorescent in situ hybridization for the enhancement of the HER2/neu quality. In this examination, we distinguished clinicopathological attributes of patients with BC. We partitioned into two gatherings, BRCA positive change and BRCA negative transformation. Roughly 5%-10% instances of BC have a positive family ancestry and about 20%-40% BC development were in acquired variations. Our study revealed that 20% of cases included individuals who had a family history of BRCA mutation. Male relatives with BC, earlier age at onset, a greater prevalence of reciprocal breast disease, and a connection to various malignancies in the ovary, colon, prostate, pancreas, and endometrial are only a few of the clear clinical characteristics of BRCA1/2-related BC.